MapLight Therapeutics, Inc.
About MapLight Therapeutics, Inc.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$161.2M
- Total assets
- $479.5M
- Market cap
- $1.3B
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $169.1M
- Operating income
- -$169.1M
- Net income
- -$161.2M
- EPS (basic)
- $-18.56
- EPS (diluted)
- $-18.56
Balance sheet
- Total assets
- $479.5M
- Current assets
- $324.7M
- Total liabilities
- $21.1M
- Current liabilities
- $16.2M
- Shareholders’ equity
- $458.4M
Cash flow
- Operating cash flow
- -$138.1M
- Investing cash flow
- -$323.2M
- Financing cash flow
- $469.8M
- Net cash flow
- $8.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.3B
- EPS (diluted)
- $-18.56
- Shares outstanding
- 43.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 27, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $161.2M.
- Trading 8% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MapLight Therapeutics, Inc..
Write a review
News about MapLight Therapeutics, Inc.
News & sentiment via Polygon.io
